[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fMKQV_q3UA6N3CnMfiFX3kW5eN5BJBdMKHvyHFE4qCK8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":35,"phaseBuckets":82,"rows":89},"Institut de Recherches Internationales Servier",[4,6],"Institut de Recherches Internationales Servier (I.R.I.S.)",72,false,15,18,46082,34,1,[15,18,21,23,26,28,31,33],{"name":16,"count":17},"Metastatic Colorectal Cancer",6,{"name":19,"count":20},"Acute Lymphoblastic Leukemia",4,{"name":22,"count":20},"Hypertension",{"name":24,"count":25},"Untreated AML",3,{"name":27,"count":25},"Glioma",{"name":29,"count":30},"Newly Diagnosed Acute Myeloid Leukemia (AML)",2,{"name":32,"count":30},"AML Arising From Myelodysplastic Syndrome (MDS)",{"name":34,"count":30},"Autism Spectrum Disorder (ASD)",[36,41,45,50,55,59,63,68,73,78],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02632708","Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and\u002For IDH2 Mutation","2018-12-13","AG-120",{"nctId":42,"briefTitle":43,"date":44,"intervention":40},"NCT03173248","Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","2021-03-18",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03869892","Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","2021-06-29","Trifluridine\u002Ftipiracil hydrochloride",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT04164901","Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)","2022-09-06","Vorasidenib",{"nctId":56,"briefTitle":57,"date":58,"intervention":54},"NCT05484622","Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma","2026-02-12",{"nctId":60,"briefTitle":61,"date":62,"intervention":40},"NCT02074839","Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation","2026-03",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT07250633","Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants","2026-07","Vorasidenib 20mg",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06501625","Ivosidenib Plus Durvalumab and Gemcitabine\u002FCisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation","2026-07-23","Ivosidenib",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06052813","A Study of BN104 in the Treatment of Acute Leukemia","2026-12","BN104 monotherapy",{"nctId":79,"briefTitle":80,"date":81,"intervention":54},"NCT06478212","Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma","2027-11",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,185,267,297,327,374,392,410,428,508,530,559,577,595,623,641,659,677,695,713,731,749,767,785,803,821,839,857,875,893,911,929,947,967,991,1058,1099,1135,1159,1177,1202,1220,1244,1269,1287,1310,1328,1346,1384,1416,1453,1475,1509,1535,1553,1578,1596,1614,1632,1658,1686,1704,1722,1746,1771,1797,1815,1833,1858,1876,1901,1926,1950,1974,1992,2029,2057,2081,2109,2127,2152,2170,2197,2222,2240,2258,2282,2300,2318,2336,2354,2378,2396,2414,2432,2450,2468,2486,2511,2536,2562,2580],{"intervention":54,"totalTrials":91,"cells":92},7,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":146,"PHASE3":169,"PHASE4":181,"NA":183},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":13,"soonestReadout":58},[98,109,120,131],{"nctId":99,"briefTitle":100,"status":101,"phases":102,"primaryCompletion":103,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":108},"NCT05674474","A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function","COMPLETED",[84],"2023-07-18","2023-03-14",16,[107],"Hepatic Impairment",[54],{"nctId":110,"briefTitle":111,"status":101,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT07235774","A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants",[84],"2026-03-13","2025-11-05",28,[117],"Healthy Adult Female Participants",[54,119],"DRSP\u002FEE",{"nctId":56,"briefTitle":57,"status":121,"phases":122,"primaryCompletion":58,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":129},"ACTIVE_NOT_RECRUITING",[84],"2027-08-30","2023-01-20",60,[127,128],"Astrocytoma","Oligodendroglioma",[54,130],"Pembrolizumab",{"nctId":132,"briefTitle":133,"status":101,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":115,"conditions":137,"interventions":139},"NCT07235748","Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants",[84],"2025-12-23","2025-10-07",[138],"Healthy Adult Participants",[54,140,141,142,143,144,145],"Bupropion","Flurbiprofen","Omeprazole","Midazolam","Repaglinide","Rosuvastatin",{"trials":147,"activeCount":30,"soonestReadout":81},[148,159],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},"NCT07286292","Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation","NOT_YET_RECRUITING",[85],"2033-05-02","2026-03-15",10,[157],"Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation",[54],{"nctId":79,"briefTitle":80,"status":121,"phases":160,"primaryCompletion":81,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":167},[84,85],"2028-06","2025-01-22",51,[165,166],"IDH1-mutant Glioma","IDH2-mutant Glioma",[54,168],"Temozolomide",{"trials":170,"activeCount":13,"soonestReadout":53},[171],{"nctId":51,"briefTitle":52,"status":121,"phases":172,"primaryCompletion":53,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":180},[86],"2028-05","2020-01-05",331,[177,178,179],"Grade 2 Glioma","Residual Glioma","Recurrent Glioma",[54],{"trials":182,"activeCount":95},[],{"trials":184,"activeCount":95},[],{"intervention":40,"totalTrials":17,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":238,"PHASE3":240,"PHASE4":263,"NA":265},{"trials":188,"activeCount":95},[],{"trials":190,"activeCount":30,"soonestReadout":39},[191,206,218,227],{"nctId":37,"briefTitle":38,"status":121,"phases":192,"primaryCompletion":39,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":199},[84],"2026-07-24","2015-12-31",153,[29,24,32,197,198],"AML Arising From Antecedent Hematologic Disorder (AHD)","AML Arising After Exposure to Genotoxic Injury",[40,200,201,202,203,204,205],"AG-221","cytarabine","daunorubicin","idarubicin","mitoxantrone","etoposide",{"nctId":207,"briefTitle":208,"status":101,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":217},"NCT02073994","Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation",[84],"2024-01-04","2014-03-01",174,[214,215,27,216],"Cholangiocarcinoma","Chondrosarcoma","Other Advanced Solid Tumors",[40],{"nctId":60,"briefTitle":61,"status":219,"phases":220,"primaryCompletion":62,"completion":62,"start":211,"enrollment":221,"conditions":222,"interventions":226},"RECRUITING",[84],291,[223,24,224,225],"Relapsed or Refractory Acute Myeloid Leukemia (AML)","Other IDH1-mutated Positive Hematologic Malignancies","Myelodysplastic Syndromes",[40],{"nctId":228,"briefTitle":229,"status":101,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":236},"NCT03343197","Study of AG-120 and AG-881 in Subjects With Low Grade Glioma",[84],"2019-08-02","2025-03-28","2018-03-20",49,[27],[40,237],"AG881",{"trials":239,"activeCount":95},[],{"trials":241,"activeCount":13,"soonestReadout":44},[242,254],{"nctId":243,"briefTitle":244,"status":101,"phases":245,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":253},"NCT02989857","Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)",[86],"2019-01-31","2021-05-17","2017-02-20",187,[251,252],"Advanced Cholangiocarcinoma","Metastatic Cholangiocarcinoma",[40],{"nctId":42,"briefTitle":43,"status":121,"phases":255,"primaryCompletion":44,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},[86],"2026-06-30","2017-06-26",146,[29,24,32,260],"Leukemia, Myeloid, Acute",[40,262],"Azacitidine",{"trials":264,"activeCount":95},[],{"trials":266,"activeCount":95},[],{"intervention":262,"totalTrials":30,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":293,"NA":295},{"trials":270,"activeCount":95},[],{"trials":272,"activeCount":95},[],{"trials":274,"activeCount":95},[],{"trials":276,"activeCount":30,"soonestReadout":44},[277,281],{"nctId":42,"briefTitle":43,"status":121,"phases":278,"primaryCompletion":44,"completion":256,"start":257,"enrollment":258,"conditions":279,"interventions":280},[86],[29,24,32,260],[40,262],{"nctId":282,"briefTitle":283,"status":219,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":292},"NCT06465953","Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation",[86],"2027-11-01","2028-12-01","2024-12-03",48,[290,291],"Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)","Myelodysplastic Syndromes (MDS)",[72,262],{"trials":294,"activeCount":95},[],{"trials":296,"activeCount":95},[],{"intervention":72,"totalTrials":30,"cells":298},{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":317,"PHASE4":323,"NA":325},{"trials":300,"activeCount":95},[],{"trials":302,"activeCount":95},[],{"trials":304,"activeCount":13,"soonestReadout":71},[305],{"nctId":69,"briefTitle":70,"status":219,"phases":306,"primaryCompletion":71,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":312},[84,85],"2027-09-13","2024-12-16",52,[311],"Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation",[72,313,314,315,313,316],"Durvalumab","Gemcitabine","Cisplatin","Ivosidenib Recommended Combination Dose",{"trials":318,"activeCount":13,"soonestReadout":285},[319],{"nctId":282,"briefTitle":283,"status":219,"phases":320,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":321,"interventions":322},[86],[290,291],[72,262],{"trials":324,"activeCount":95},[],{"trials":326,"activeCount":95},[],{"intervention":49,"totalTrials":25,"cells":328},{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":346,"PHASE3":348,"PHASE4":370,"NA":372},{"trials":330,"activeCount":95},[],{"trials":332,"activeCount":95},[333],{"nctId":334,"briefTitle":335,"status":101,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":342},"NCT02848443","Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer",[84],"2019-08-01","2020-04-09","2016-05",78,[16],[49,343,344,345],"Oxaliplatin","Bevacizumab","Nivolumab",{"trials":347,"activeCount":95},[],{"trials":349,"activeCount":13,"soonestReadout":48},[350,360],{"nctId":46,"briefTitle":47,"status":121,"phases":351,"primaryCompletion":48,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":356},[86],"2026-12-31","2019-03-21",856,[16],[49,357,358,359],"Capecitabine","Bevacizumab experimental","Bevacizumab control",{"nctId":361,"briefTitle":362,"status":101,"phases":363,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":368},"NCT03306394","A Study of Trifluridine\u002FTipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).",[86],"2020-11-30","2016-10-18",907,[16],[369],"Trifluridine\u002FTipiracil hydrochloride",{"trials":371,"activeCount":95},[],{"trials":373,"activeCount":95},[],{"intervention":357,"totalTrials":13,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":388,"NA":390},{"trials":377,"activeCount":95},[],{"trials":379,"activeCount":95},[],{"trials":381,"activeCount":95},[],{"trials":383,"activeCount":13,"soonestReadout":48},[384],{"nctId":46,"briefTitle":47,"status":121,"phases":385,"primaryCompletion":48,"completion":352,"start":353,"enrollment":354,"conditions":386,"interventions":387},[86],[16],[49,357,358,359],{"trials":389,"activeCount":95},[],{"trials":391,"activeCount":95},[],{"intervention":358,"totalTrials":13,"cells":393},{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":400,"PHASE4":406,"NA":408},{"trials":395,"activeCount":95},[],{"trials":397,"activeCount":95},[],{"trials":399,"activeCount":95},[],{"trials":401,"activeCount":13,"soonestReadout":48},[402],{"nctId":46,"briefTitle":47,"status":121,"phases":403,"primaryCompletion":48,"completion":352,"start":353,"enrollment":354,"conditions":404,"interventions":405},[86],[16],[49,357,358,359],{"trials":407,"activeCount":95},[],{"trials":409,"activeCount":95},[],{"intervention":359,"totalTrials":13,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":424,"NA":426},{"trials":413,"activeCount":95},[],{"trials":415,"activeCount":95},[],{"trials":417,"activeCount":95},[],{"trials":419,"activeCount":13,"soonestReadout":48},[420],{"nctId":46,"briefTitle":47,"status":121,"phases":421,"primaryCompletion":48,"completion":352,"start":353,"enrollment":354,"conditions":422,"interventions":423},[86],[16],[49,357,358,359],{"trials":425,"activeCount":95},[],{"trials":427,"activeCount":95},[],{"intervention":314,"totalTrials":25,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":450,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":431,"activeCount":95},[],{"trials":433,"activeCount":95},[434],{"nctId":435,"briefTitle":436,"status":437,"phases":438,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":442,"interventions":445},"NCT03435250","Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss","TERMINATED",[84],"2023-04-20","2018-03-04",123,[443,444],"Advanced Solid Tumors","Lymphoma",[446,446,446,447,448,449],"AG-270","docetaxel","nab-paclitaxel","gemcitabine",{"trials":451,"activeCount":30,"soonestReadout":71},[452,456],{"nctId":69,"briefTitle":70,"status":219,"phases":453,"primaryCompletion":71,"completion":307,"start":308,"enrollment":309,"conditions":454,"interventions":455},[84,85],[311],[72,313,314,315,313,316],{"nctId":457,"briefTitle":458,"status":219,"phases":459,"primaryCompletion":161,"completion":161,"start":460,"enrollment":461,"conditions":462,"interventions":495},"NCT05786924","Phase 1\u002F2 Trial of S241656 in Selected RAS\u002FMAPK Mutation- Positive Malignancies",[84,85],"2023-04-18",554,[463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494],"Non-small Cell Lung Cancer","Histiocytic Neoplasm","Histiocytosis","BRAF Gene Mutation","BRAF V600E","BRAF V600 Mutation","BRAF Mutation-Related Tumors","BRAF","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Cancer","Recurrent Lung Cancer","Recurrent Lung Non-Small Cell Carcinoma","NSCLC","Solid Tumor","Solid Carcinoma","KRAS G12D","KRAS G12V","KRAS Mutation-Related Tumors","NRAS Gene Mutation","Thyroid Cancer","Thyroid Carcinoma","Colorectal Cancer","Colorectal Carcinoma","Recurrent Histiocytic and Dendritic Cell Neoplasm","Brain Metastases","Recurrent NSCLC","KRAS G13C","Acquired Resistance to KRAS G12C Inhibitor","KRAS G12A","KRAS G12F","KRAS G12R","KRAS G13D",[496,497,498,499,500,314,501],"S241656","FOLFOX6\u002FFOLFOX7","FOLFIRI","Cetuximab","Panitumumab","Nab-paclitaxel",{"trials":503,"activeCount":95},[],{"trials":505,"activeCount":95},[],{"trials":507,"activeCount":95},[],{"intervention":448,"totalTrials":30,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":518,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":511,"activeCount":95},[],{"trials":513,"activeCount":95},[514],{"nctId":435,"briefTitle":436,"status":437,"phases":515,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":516,"interventions":517},[84],[443,444],[446,446,446,447,448,449],{"trials":519,"activeCount":13,"soonestReadout":161},[520],{"nctId":457,"briefTitle":458,"status":219,"phases":521,"primaryCompletion":161,"completion":161,"start":460,"enrollment":461,"conditions":522,"interventions":523},[84,85],[463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494],[496,497,498,499,500,314,501],{"trials":525,"activeCount":95},[],{"trials":527,"activeCount":95},[],{"trials":529,"activeCount":95},[],{"intervention":77,"totalTrials":13,"cells":531},{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":533,"activeCount":95},[],{"trials":535,"activeCount":95},[],{"trials":537,"activeCount":13,"soonestReadout":76},[538],{"nctId":74,"briefTitle":75,"status":121,"phases":539,"primaryCompletion":76,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":551},[84,85],"2027-12","2023-10-19",66,[544,545,546,547,548,549,550],"ALL, Adult","AML, Adult","Acute Leukaemia","KMT2A Rearrangement","NPM1 Mutation","NUP98 Gene Rearrangement","Menin Inhibitors",[77,77,552],"BN104 monotherapy - rp2d",{"trials":554,"activeCount":95},[],{"trials":556,"activeCount":95},[],{"trials":558,"activeCount":95},[],{"intervention":552,"totalTrials":13,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":571,"PHASE4":573,"NA":575},{"trials":562,"activeCount":95},[],{"trials":564,"activeCount":95},[],{"trials":566,"activeCount":13,"soonestReadout":76},[567],{"nctId":74,"briefTitle":75,"status":121,"phases":568,"primaryCompletion":76,"completion":540,"start":541,"enrollment":542,"conditions":569,"interventions":570},[84,85],[544,545,546,547,548,549,550],[77,77,552],{"trials":572,"activeCount":95},[],{"trials":574,"activeCount":95},[],{"trials":576,"activeCount":95},[],{"intervention":168,"totalTrials":13,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":589,"PHASE4":591,"NA":593},{"trials":580,"activeCount":95},[],{"trials":582,"activeCount":95},[],{"trials":584,"activeCount":13,"soonestReadout":81},[585],{"nctId":79,"briefTitle":80,"status":121,"phases":586,"primaryCompletion":81,"completion":161,"start":162,"enrollment":163,"conditions":587,"interventions":588},[84,85],[165,166],[54,168],{"trials":590,"activeCount":95},[],{"trials":592,"activeCount":95},[],{"trials":594,"activeCount":95},[],{"intervention":596,"totalTrials":13,"cells":597},"S230815- Starting dose A",{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":617,"PHASE4":619,"NA":621},{"trials":599,"activeCount":95},[],{"trials":601,"activeCount":95},[],{"trials":603,"activeCount":13,"soonestReadout":608},[604],{"nctId":605,"briefTitle":606,"status":219,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":613},"NCT07227857","A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy",[84,85],"2028-04-15","2025-11-24",20,[612],"Epileptic Encephalopathy",[596,614,615,616],"S230815- Dose B","S230815- Dose C","S230815- Dose D",{"trials":618,"activeCount":95},[],{"trials":620,"activeCount":95},[],{"trials":622,"activeCount":95},[],{"intervention":614,"totalTrials":13,"cells":624},{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":635,"PHASE4":637,"NA":639},{"trials":626,"activeCount":95},[],{"trials":628,"activeCount":95},[],{"trials":630,"activeCount":13,"soonestReadout":608},[631],{"nctId":605,"briefTitle":606,"status":219,"phases":632,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":633,"interventions":634},[84,85],[612],[596,614,615,616],{"trials":636,"activeCount":95},[],{"trials":638,"activeCount":95},[],{"trials":640,"activeCount":95},[],{"intervention":615,"totalTrials":13,"cells":642},{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":653,"PHASE4":655,"NA":657},{"trials":644,"activeCount":95},[],{"trials":646,"activeCount":95},[],{"trials":648,"activeCount":13,"soonestReadout":608},[649],{"nctId":605,"briefTitle":606,"status":219,"phases":650,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":651,"interventions":652},[84,85],[612],[596,614,615,616],{"trials":654,"activeCount":95},[],{"trials":656,"activeCount":95},[],{"trials":658,"activeCount":95},[],{"intervention":616,"totalTrials":13,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":662,"activeCount":95},[],{"trials":664,"activeCount":95},[],{"trials":666,"activeCount":13,"soonestReadout":608},[667],{"nctId":605,"briefTitle":606,"status":219,"phases":668,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":669,"interventions":670},[84,85],[612],[596,614,615,616],{"trials":672,"activeCount":95},[],{"trials":674,"activeCount":95},[],{"trials":676,"activeCount":95},[],{"intervention":313,"totalTrials":13,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":689,"PHASE4":691,"NA":693},{"trials":680,"activeCount":95},[],{"trials":682,"activeCount":95},[],{"trials":684,"activeCount":13,"soonestReadout":71},[685],{"nctId":69,"briefTitle":70,"status":219,"phases":686,"primaryCompletion":71,"completion":307,"start":308,"enrollment":309,"conditions":687,"interventions":688},[84,85],[311],[72,313,314,315,313,316],{"trials":690,"activeCount":95},[],{"trials":692,"activeCount":95},[],{"trials":694,"activeCount":95},[],{"intervention":315,"totalTrials":13,"cells":696},{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":698,"activeCount":95},[],{"trials":700,"activeCount":95},[],{"trials":702,"activeCount":13,"soonestReadout":71},[703],{"nctId":69,"briefTitle":70,"status":219,"phases":704,"primaryCompletion":71,"completion":307,"start":308,"enrollment":309,"conditions":705,"interventions":706},[84,85],[311],[72,313,314,315,313,316],{"trials":708,"activeCount":95},[],{"trials":710,"activeCount":95},[],{"trials":712,"activeCount":95},[],{"intervention":316,"totalTrials":13,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":716,"activeCount":95},[],{"trials":718,"activeCount":95},[],{"trials":720,"activeCount":13,"soonestReadout":71},[721],{"nctId":69,"briefTitle":70,"status":219,"phases":722,"primaryCompletion":71,"completion":307,"start":308,"enrollment":309,"conditions":723,"interventions":724},[84,85],[311],[72,313,314,315,313,316],{"trials":726,"activeCount":95},[],{"trials":728,"activeCount":95},[],{"trials":730,"activeCount":95},[],{"intervention":496,"totalTrials":13,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":734,"activeCount":95},[],{"trials":736,"activeCount":95},[],{"trials":738,"activeCount":13,"soonestReadout":161},[739],{"nctId":457,"briefTitle":458,"status":219,"phases":740,"primaryCompletion":161,"completion":161,"start":460,"enrollment":461,"conditions":741,"interventions":742},[84,85],[463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494],[496,497,498,499,500,314,501],{"trials":744,"activeCount":95},[],{"trials":746,"activeCount":95},[],{"trials":748,"activeCount":95},[],{"intervention":497,"totalTrials":13,"cells":750},{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":761,"PHASE4":763,"NA":765},{"trials":752,"activeCount":95},[],{"trials":754,"activeCount":95},[],{"trials":756,"activeCount":13,"soonestReadout":161},[757],{"nctId":457,"briefTitle":458,"status":219,"phases":758,"primaryCompletion":161,"completion":161,"start":460,"enrollment":461,"conditions":759,"interventions":760},[84,85],[463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494],[496,497,498,499,500,314,501],{"trials":762,"activeCount":95},[],{"trials":764,"activeCount":95},[],{"trials":766,"activeCount":95},[],{"intervention":498,"totalTrials":13,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":779,"PHASE4":781,"NA":783},{"trials":770,"activeCount":95},[],{"trials":772,"activeCount":95},[],{"trials":774,"activeCount":13,"soonestReadout":161},[775],{"nctId":457,"briefTitle":458,"status":219,"phases":776,"primaryCompletion":161,"completion":161,"start":460,"enrollment":461,"conditions":777,"interventions":778},[84,85],[463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494],[496,497,498,499,500,314,501],{"trials":780,"activeCount":95},[],{"trials":782,"activeCount":95},[],{"trials":784,"activeCount":95},[],{"intervention":499,"totalTrials":13,"cells":786},{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":797,"PHASE4":799,"NA":801},{"trials":788,"activeCount":95},[],{"trials":790,"activeCount":95},[],{"trials":792,"activeCount":13,"soonestReadout":161},[793],{"nctId":457,"briefTitle":458,"status":219,"phases":794,"primaryCompletion":161,"completion":161,"start":460,"enrollment":461,"conditions":795,"interventions":796},[84,85],[463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494],[496,497,498,499,500,314,501],{"trials":798,"activeCount":95},[],{"trials":800,"activeCount":95},[],{"trials":802,"activeCount":95},[],{"intervention":500,"totalTrials":13,"cells":804},{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":806,"activeCount":95},[],{"trials":808,"activeCount":95},[],{"trials":810,"activeCount":13,"soonestReadout":161},[811],{"nctId":457,"briefTitle":458,"status":219,"phases":812,"primaryCompletion":161,"completion":161,"start":460,"enrollment":461,"conditions":813,"interventions":814},[84,85],[463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494],[496,497,498,499,500,314,501],{"trials":816,"activeCount":95},[],{"trials":818,"activeCount":95},[],{"trials":820,"activeCount":95},[],{"intervention":200,"totalTrials":13,"cells":822},{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":831,"PHASE3":833,"PHASE4":835,"NA":837},{"trials":824,"activeCount":95},[],{"trials":826,"activeCount":13,"soonestReadout":39},[827],{"nctId":37,"briefTitle":38,"status":121,"phases":828,"primaryCompletion":39,"completion":193,"start":194,"enrollment":195,"conditions":829,"interventions":830},[84],[29,24,32,197,198],[40,200,201,202,203,204,205],{"trials":832,"activeCount":95},[],{"trials":834,"activeCount":95},[],{"trials":836,"activeCount":95},[],{"trials":838,"activeCount":95},[],{"intervention":201,"totalTrials":13,"cells":840},{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":849,"PHASE3":851,"PHASE4":853,"NA":855},{"trials":842,"activeCount":95},[],{"trials":844,"activeCount":13,"soonestReadout":39},[845],{"nctId":37,"briefTitle":38,"status":121,"phases":846,"primaryCompletion":39,"completion":193,"start":194,"enrollment":195,"conditions":847,"interventions":848},[84],[29,24,32,197,198],[40,200,201,202,203,204,205],{"trials":850,"activeCount":95},[],{"trials":852,"activeCount":95},[],{"trials":854,"activeCount":95},[],{"trials":856,"activeCount":95},[],{"intervention":202,"totalTrials":13,"cells":858},{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":860,"activeCount":95},[],{"trials":862,"activeCount":13,"soonestReadout":39},[863],{"nctId":37,"briefTitle":38,"status":121,"phases":864,"primaryCompletion":39,"completion":193,"start":194,"enrollment":195,"conditions":865,"interventions":866},[84],[29,24,32,197,198],[40,200,201,202,203,204,205],{"trials":868,"activeCount":95},[],{"trials":870,"activeCount":95},[],{"trials":872,"activeCount":95},[],{"trials":874,"activeCount":95},[],{"intervention":203,"totalTrials":13,"cells":876},{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":885,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":878,"activeCount":95},[],{"trials":880,"activeCount":13,"soonestReadout":39},[881],{"nctId":37,"briefTitle":38,"status":121,"phases":882,"primaryCompletion":39,"completion":193,"start":194,"enrollment":195,"conditions":883,"interventions":884},[84],[29,24,32,197,198],[40,200,201,202,203,204,205],{"trials":886,"activeCount":95},[],{"trials":888,"activeCount":95},[],{"trials":890,"activeCount":95},[],{"trials":892,"activeCount":95},[],{"intervention":204,"totalTrials":13,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":903,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":896,"activeCount":95},[],{"trials":898,"activeCount":13,"soonestReadout":39},[899],{"nctId":37,"briefTitle":38,"status":121,"phases":900,"primaryCompletion":39,"completion":193,"start":194,"enrollment":195,"conditions":901,"interventions":902},[84],[29,24,32,197,198],[40,200,201,202,203,204,205],{"trials":904,"activeCount":95},[],{"trials":906,"activeCount":95},[],{"trials":908,"activeCount":95},[],{"trials":910,"activeCount":95},[],{"intervention":205,"totalTrials":13,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":921,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":914,"activeCount":95},[],{"trials":916,"activeCount":13,"soonestReadout":39},[917],{"nctId":37,"briefTitle":38,"status":121,"phases":918,"primaryCompletion":39,"completion":193,"start":194,"enrollment":195,"conditions":919,"interventions":920},[84],[29,24,32,197,198],[40,200,201,202,203,204,205],{"trials":922,"activeCount":95},[],{"trials":924,"activeCount":95},[],{"trials":926,"activeCount":95},[],{"trials":928,"activeCount":95},[],{"intervention":130,"totalTrials":13,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":939,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":932,"activeCount":95},[],{"trials":934,"activeCount":13,"soonestReadout":58},[935],{"nctId":56,"briefTitle":57,"status":121,"phases":936,"primaryCompletion":58,"completion":123,"start":124,"enrollment":125,"conditions":937,"interventions":938},[84],[127,128],[54,130],{"trials":940,"activeCount":95},[],{"trials":942,"activeCount":95},[],{"trials":944,"activeCount":95},[],{"trials":946,"activeCount":95},[],{"intervention":67,"totalTrials":13,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":959,"PHASE3":961,"PHASE4":963,"NA":965},{"trials":950,"activeCount":95},[],{"trials":952,"activeCount":13,"soonestReadout":66},[953],{"nctId":64,"briefTitle":65,"status":151,"phases":954,"primaryCompletion":66,"completion":66,"start":62,"enrollment":610,"conditions":955,"interventions":958},[84],[956,957],"Severe Hepatic Impairment","Normal Hepatic Function",[67],{"trials":960,"activeCount":95},[],{"trials":962,"activeCount":95},[],{"trials":964,"activeCount":95},[],{"trials":966,"activeCount":95},[],{"intervention":968,"totalTrials":13,"cells":969},"UCART19 follow-up",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":983,"PHASE3":985,"PHASE4":987,"NA":989},{"trials":971,"activeCount":95},[],{"trials":973,"activeCount":13,"soonestReadout":978},[974],{"nctId":975,"briefTitle":976,"status":121,"phases":977,"primaryCompletion":978,"completion":978,"start":979,"enrollment":115,"conditions":980,"interventions":982},"NCT02735083","A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19",[84],"2028-09","2021-03-10",[981],"Advanced Lymphoid Leukemia",[968],{"trials":984,"activeCount":95},[],{"trials":986,"activeCount":95},[],{"trials":988,"activeCount":95},[],{"trials":990,"activeCount":95},[],{"intervention":992,"totalTrials":993,"cells":994},"Ivabradine",5,{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1011,"PHASE4":1054,"NA":1056},{"trials":996,"activeCount":95},[],{"trials":998,"activeCount":95},[],{"trials":1000,"activeCount":95},[1001],{"nctId":1002,"briefTitle":1003,"status":101,"phases":1004,"completion":1005,"start":1006,"enrollment":1007,"conditions":1008,"interventions":1010},"NCT00202579","Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure",[85],"2006-02","2004-09",12,[1009],"Heart Failure, Congestive",[992],{"trials":1012,"activeCount":95},[1013,1023,1034,1044],{"nctId":1014,"briefTitle":1015,"status":101,"phases":1016,"primaryCompletion":1017,"completion":1017,"start":1018,"enrollment":1019,"conditions":1020,"interventions":1022},"NCT02441218","Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study",[86],"2010-04","2006-09",6505,[1021],"Chronic Heart Failure",[992],{"nctId":1024,"briefTitle":1025,"status":101,"phases":1026,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1033},"NCT00143507","The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction",[86],"2008-02","2004-12",10917,[1031,1032],"Coronary Disease","Ventricular Dysfunction, Left",[992],{"nctId":1035,"briefTitle":1036,"status":101,"phases":1037,"completion":1038,"start":1039,"enrollment":1040,"conditions":1041,"interventions":1043},"NCT00202566","Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris",[86],"2007-10","2005-06",750,[1042],"Angina Pectoris",[992],{"nctId":1045,"briefTitle":1046,"status":101,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":1050,"conditions":1051,"interventions":1053},"NCT02446990","Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure",[86],"2014-01","2009-09",19102,[1052],"Coronary Artery Disease",[992],{"trials":1055,"activeCount":95},[],{"trials":1057,"activeCount":95},[],{"intervention":1059,"totalTrials":25,"cells":1060},"Perindopril",{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1082,"PHASE4":1095,"NA":1097},{"trials":1062,"activeCount":95},[],{"trials":1064,"activeCount":95},[],{"trials":1066,"activeCount":95},[1067,1076],{"nctId":1068,"briefTitle":1069,"status":101,"phases":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1075},"NCT00202553","S90652 in Paediatric Hypertension",[85],"2006-12","2003-07",50,[22],[1059],{"nctId":1077,"briefTitle":1069,"status":101,"phases":1078,"primaryCompletion":1017,"completion":1017,"start":1079,"enrollment":1073,"conditions":1080,"interventions":1081},"NCT00202592",[85],"2003-11",[22],[1059],{"trials":1083,"activeCount":95},[1084],{"nctId":1085,"briefTitle":1086,"status":437,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":258,"conditions":1090,"interventions":1092},"NCT04591808","Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia",[86],"2022-04-08","2021-09-09",[1091,22],"Dyslipidemias",[1093,1094,1059],"Atorvastatin\u002FPerindopril","Atorvastatin",{"trials":1096,"activeCount":95},[],{"trials":1098,"activeCount":95},[],{"intervention":1100,"totalTrials":30,"cells":1101},"Gevokizumab",{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1131,"NA":1133},{"trials":1103,"activeCount":95},[],{"trials":1105,"activeCount":95},[],{"trials":1107,"activeCount":95},[],{"trials":1109,"activeCount":95},[1110,1121],{"nctId":1111,"briefTitle":1112,"status":437,"phases":1113,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":1117,"conditions":1118,"interventions":1120},"NCT01965145","Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)",[86],"2015-07","2015-09","2012-11",84,[1119],"Behcet's Uveitis",[1100],{"nctId":1122,"briefTitle":1123,"status":437,"phases":1124,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":1127,"conditions":1128,"interventions":1130},"NCT02375685","Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)",[86],"2015-11","2014-08",71,[1129],"Chronic Uveitis",[1100],{"trials":1132,"activeCount":95},[],{"trials":1134,"activeCount":95},[],{"intervention":1136,"totalTrials":13,"cells":1137},"Futuximab\u002Fmodotuximab",{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1142,"PHASE3":1144,"PHASE4":1155,"NA":1157},{"trials":1139,"activeCount":95},[],{"trials":1141,"activeCount":95},[],{"trials":1143,"activeCount":95},[],{"trials":1145,"activeCount":95},[1146],{"nctId":1147,"briefTitle":1148,"status":437,"phases":1149,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":91,"conditions":1152,"interventions":1153},"NCT05223673","Phase 3 Study of Futuximab\u002FModotuximab in Combination With Trifluridine\u002FTipiracil Versus Trifluridine\u002FTipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer",[86],"2023-06-21","2022-04-21",[16],[1136,1154,1154],"Trifluridine\u002FTipiracil",{"trials":1156,"activeCount":95},[],{"trials":1158,"activeCount":95},[],{"intervention":1154,"totalTrials":13,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1167,"PHASE4":1173,"NA":1175},{"trials":1162,"activeCount":95},[],{"trials":1164,"activeCount":95},[],{"trials":1166,"activeCount":95},[],{"trials":1168,"activeCount":95},[1169],{"nctId":1147,"briefTitle":1148,"status":437,"phases":1170,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":91,"conditions":1171,"interventions":1172},[86],[16],[1136,1154,1154],{"trials":1174,"activeCount":95},[],{"trials":1176,"activeCount":95},[],{"intervention":1178,"totalTrials":13,"cells":1179},"BUMETANIDE (S95008) for week 0 - 26",{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1184,"PHASE3":1186,"PHASE4":1198,"NA":1200},{"trials":1181,"activeCount":95},[],{"trials":1183,"activeCount":95},[],{"trials":1185,"activeCount":95},[],{"trials":1187,"activeCount":95},[1188],{"nctId":1189,"briefTitle":1190,"status":437,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":1194,"conditions":1195,"interventions":1196},"NCT03715153","Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.",[86],"2021-10-26","2018-10-04",211,[34],[1178,1197],"Open-Label BUMETANIDE (S95008) for weeks 26 - 52",{"trials":1199,"activeCount":95},[],{"trials":1201,"activeCount":95},[],{"intervention":1197,"totalTrials":13,"cells":1203},{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1208,"PHASE3":1210,"PHASE4":1216,"NA":1218},{"trials":1205,"activeCount":95},[],{"trials":1207,"activeCount":95},[],{"trials":1209,"activeCount":95},[],{"trials":1211,"activeCount":95},[1212],{"nctId":1189,"briefTitle":1190,"status":437,"phases":1213,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":1194,"conditions":1214,"interventions":1215},[86],[34],[1178,1197],{"trials":1217,"activeCount":95},[],{"trials":1219,"activeCount":95},[],{"intervention":1221,"totalTrials":13,"cells":1222},"Calaspargase pegol",{"EARLY_PHASE1":1223,"PHASE1":1225,"PHASE2":1227,"PHASE3":1229,"PHASE4":1240,"NA":1242},{"trials":1224,"activeCount":95},[],{"trials":1226,"activeCount":95},[],{"trials":1228,"activeCount":95},[],{"trials":1230,"activeCount":95},[1231],{"nctId":1232,"briefTitle":1233,"status":437,"phases":1234,"primaryCompletion":1235,"completion":1235,"start":1236,"enrollment":1237,"conditions":1238,"interventions":1239},"NCT04817761","SPARK-ALL: Calaspargase Pegol in Adults With ALL",[85,86],"2025-03-21","2021-07-07",42,[19],[1221],{"trials":1241,"activeCount":95},[],{"trials":1243,"activeCount":95},[],{"intervention":1245,"totalTrials":13,"cells":1246},"Fixed [Per\u002FInd\u002FAml]",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1265,"NA":1267},{"trials":1248,"activeCount":95},[],{"trials":1250,"activeCount":95},[],{"trials":1252,"activeCount":95},[],{"trials":1254,"activeCount":95},[1255],{"nctId":1256,"briefTitle":1257,"status":101,"phases":1258,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":1262,"interventions":1263},"NCT05820880","Efficacy and Safety of Perindopril 5 mg \u002F Indapamide 1.25 mg \u002F Amlodipine 5 mg Fixed Combination in Hypertension",[86],"2022-02-23","2019-05-06",532,[22],[1245,1264],"Free [Per\u002FInd + Aml]",{"trials":1266,"activeCount":95},[],{"trials":1268,"activeCount":95},[],{"intervention":1264,"totalTrials":13,"cells":1270},{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1277,"PHASE4":1283,"NA":1285},{"trials":1272,"activeCount":95},[],{"trials":1274,"activeCount":95},[],{"trials":1276,"activeCount":95},[],{"trials":1278,"activeCount":95},[1279],{"nctId":1256,"briefTitle":1257,"status":101,"phases":1280,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":1281,"interventions":1282},[86],[22],[1245,1264],{"trials":1284,"activeCount":95},[],{"trials":1286,"activeCount":95},[],{"intervention":1288,"totalTrials":13,"cells":1289},"Bumetanide Oral Solution",{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1296,"PHASE4":1306,"NA":1308},{"trials":1291,"activeCount":95},[],{"trials":1293,"activeCount":95},[],{"trials":1295,"activeCount":95},[],{"trials":1297,"activeCount":95},[1298],{"nctId":1299,"briefTitle":1300,"status":437,"phases":1301,"primaryCompletion":1302,"completion":1302,"start":1303,"enrollment":1194,"conditions":1304,"interventions":1305},"NCT03715166","Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder",[86],"2021-09-13","2018-09-24",[34],[1288],{"trials":1307,"activeCount":95},[],{"trials":1309,"activeCount":95},[],{"intervention":1093,"totalTrials":13,"cells":1311},{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1324,"NA":1326},{"trials":1313,"activeCount":95},[],{"trials":1315,"activeCount":95},[],{"trials":1317,"activeCount":95},[],{"trials":1319,"activeCount":95},[1320],{"nctId":1085,"briefTitle":1086,"status":437,"phases":1321,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":258,"conditions":1322,"interventions":1323},[86],[1091,22],[1093,1094,1059],{"trials":1325,"activeCount":95},[],{"trials":1327,"activeCount":95},[],{"intervention":1094,"totalTrials":13,"cells":1329},{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1336,"PHASE4":1342,"NA":1344},{"trials":1331,"activeCount":95},[],{"trials":1333,"activeCount":95},[],{"trials":1335,"activeCount":95},[],{"trials":1337,"activeCount":95},[1338],{"nctId":1085,"briefTitle":1086,"status":437,"phases":1339,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":258,"conditions":1340,"interventions":1341},[86],[1091,22],[1093,1094,1059],{"trials":1343,"activeCount":95},[],{"trials":1345,"activeCount":95},[],{"intervention":1347,"totalTrials":30,"cells":1348},"lucitanib",{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1350,"activeCount":95},[],{"trials":1352,"activeCount":95},[],{"trials":1354,"activeCount":95},[1355,1366],{"nctId":1356,"briefTitle":1357,"status":101,"phases":1358,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1365},"NCT02053636","A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer",[85],"2017-03","2017-04-04","2013-12",76,[1364],"Breast Cancer",[1347],{"nctId":1367,"briefTitle":1368,"status":101,"phases":1369,"primaryCompletion":1370,"completion":1371,"start":1372,"enrollment":1373,"conditions":1374,"interventions":1376},"NCT01283945","Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors",[84,85],"2016-09","2017-05-04","2010-07",134,[1375],"Solid Tumors",[1377],"Lucitanib",{"trials":1379,"activeCount":95},[],{"trials":1381,"activeCount":95},[],{"trials":1383,"activeCount":95},[],{"intervention":343,"totalTrials":30,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1394,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1387,"activeCount":95},[],{"trials":1389,"activeCount":95},[1390],{"nctId":334,"briefTitle":335,"status":101,"phases":1391,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1392,"interventions":1393},[84],[16],[49,343,344,345],{"trials":1395,"activeCount":95},[1396],{"nctId":1397,"briefTitle":1398,"status":101,"phases":1399,"primaryCompletion":1400,"completion":1401,"start":1402,"enrollment":1403,"conditions":1404,"interventions":1406},"NCT06225999","Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil\u002FLevoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas",[85],"2025-04-28","2025-09-29","2024-04-25",41,[1405],"Metastatic Adenocarcinoma of the Pancreas",[1407,343,1408,1409],"Irinotecan liposome","LLV","5- FU",{"trials":1411,"activeCount":95},[],{"trials":1413,"activeCount":95},[],{"trials":1415,"activeCount":95},[],{"intervention":1417,"totalTrials":30,"cells":1418},"S47445 15mg",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1420,"activeCount":95},[],{"trials":1422,"activeCount":95},[],{"trials":1424,"activeCount":95},[1425,1436],{"nctId":1426,"briefTitle":1427,"status":101,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1434},"NCT02805439","Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment",[85],"2017-04","2016-03",400,[1433],"Major Depressive Disorder",[1417,1435],"S47445 50mg",{"nctId":1437,"briefTitle":1438,"status":101,"phases":1439,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":1443,"interventions":1445},"NCT02626572","Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms",[85],"2017-09","2015-02",500,[1444],"Alzheimer's Disease",[1446,1417,1435],"S47445 5mg",{"trials":1448,"activeCount":95},[],{"trials":1450,"activeCount":95},[],{"trials":1452,"activeCount":95},[],{"intervention":1435,"totalTrials":30,"cells":1454},{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1469,"PHASE4":1471,"NA":1473},{"trials":1456,"activeCount":95},[],{"trials":1458,"activeCount":95},[],{"trials":1460,"activeCount":95},[1461,1465],{"nctId":1426,"briefTitle":1427,"status":101,"phases":1462,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1463,"interventions":1464},[85],[1433],[1417,1435],{"nctId":1437,"briefTitle":1438,"status":101,"phases":1466,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":1467,"interventions":1468},[85],[1444],[1446,1417,1435],{"trials":1470,"activeCount":95},[],{"trials":1472,"activeCount":95},[],{"trials":1474,"activeCount":95},[],{"intervention":1476,"totalTrials":30,"cells":1477},"Lyophilized S95014",{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1503,"PHASE4":1505,"NA":1507},{"trials":1479,"activeCount":95},[],{"trials":1481,"activeCount":95},[],{"trials":1483,"activeCount":95},[1484,1494],{"nctId":1485,"briefTitle":1486,"status":101,"phases":1487,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1490,"conditions":1491,"interventions":1492},"NCT04954326","A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)",[85],"2022-05-20","2021-05-07",89,[19],[1476,1493],"Liquid S95014",{"nctId":1495,"briefTitle":1496,"status":101,"phases":1497,"primaryCompletion":1498,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1502},"NCT04956666","A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)",[85],"2023-01-23","2021-06-15",75,[19],[1476],{"trials":1504,"activeCount":95},[],{"trials":1506,"activeCount":95},[],{"trials":1508,"activeCount":95},[],{"intervention":1510,"totalTrials":13,"cells":1511},"Trifluridine\u002Ftipiracil + bevacizumab",{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1529,"PHASE4":1531,"NA":1533},{"trials":1513,"activeCount":95},[],{"trials":1515,"activeCount":95},[],{"trials":1517,"activeCount":95},[1518],{"nctId":1519,"briefTitle":1520,"status":101,"phases":1521,"primaryCompletion":1522,"completion":1523,"start":1524,"enrollment":1525,"conditions":1526,"interventions":1527},"NCT02743221","A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy",[85],"2018-01-15","2020-09-01","2016-04-29",154,[16],[1510,1528],"Capecitabine + bevacizumab",{"trials":1530,"activeCount":95},[],{"trials":1532,"activeCount":95},[],{"trials":1534,"activeCount":95},[],{"intervention":1528,"totalTrials":13,"cells":1536},{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1538,"activeCount":95},[],{"trials":1540,"activeCount":95},[],{"trials":1542,"activeCount":95},[1543],{"nctId":1519,"briefTitle":1520,"status":101,"phases":1544,"primaryCompletion":1522,"completion":1523,"start":1524,"enrollment":1525,"conditions":1545,"interventions":1546},[85],[16],[1510,1528],{"trials":1548,"activeCount":95},[],{"trials":1550,"activeCount":95},[],{"trials":1552,"activeCount":95},[],{"intervention":1554,"totalTrials":13,"cells":1555},"S95011 concentrate for solution for",{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1572,"PHASE4":1574,"NA":1576},{"trials":1557,"activeCount":95},[],{"trials":1559,"activeCount":95},[],{"trials":1561,"activeCount":95},[1562],{"nctId":1563,"briefTitle":1564,"status":101,"phases":1565,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":288,"conditions":1569,"interventions":1571},"NCT04605978","Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients",[85],"2023-01-16","2023-05-09","2021-08-03",[1570],"Primary Sjögren's Syndrome",[1554],{"trials":1573,"activeCount":95},[],{"trials":1575,"activeCount":95},[],{"trials":1577,"activeCount":95},[],{"intervention":1407,"totalTrials":13,"cells":1579},{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1590,"PHASE4":1592,"NA":1594},{"trials":1581,"activeCount":95},[],{"trials":1583,"activeCount":95},[],{"trials":1585,"activeCount":95},[1586],{"nctId":1397,"briefTitle":1398,"status":101,"phases":1587,"primaryCompletion":1400,"completion":1401,"start":1402,"enrollment":1403,"conditions":1588,"interventions":1589},[85],[1405],[1407,343,1408,1409],{"trials":1591,"activeCount":95},[],{"trials":1593,"activeCount":95},[],{"trials":1595,"activeCount":95},[],{"intervention":1408,"totalTrials":13,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1608,"PHASE4":1610,"NA":1612},{"trials":1599,"activeCount":95},[],{"trials":1601,"activeCount":95},[],{"trials":1603,"activeCount":95},[1604],{"nctId":1397,"briefTitle":1398,"status":101,"phases":1605,"primaryCompletion":1400,"completion":1401,"start":1402,"enrollment":1403,"conditions":1606,"interventions":1607},[85],[1405],[1407,343,1408,1409],{"trials":1609,"activeCount":95},[],{"trials":1611,"activeCount":95},[],{"trials":1613,"activeCount":95},[],{"intervention":1409,"totalTrials":13,"cells":1615},{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1617,"activeCount":95},[],{"trials":1619,"activeCount":95},[],{"trials":1621,"activeCount":95},[1622],{"nctId":1397,"briefTitle":1398,"status":101,"phases":1623,"primaryCompletion":1400,"completion":1401,"start":1402,"enrollment":1403,"conditions":1624,"interventions":1625},[85],[1405],[1407,343,1408,1409],{"trials":1627,"activeCount":95},[],{"trials":1629,"activeCount":95},[],{"trials":1631,"activeCount":95},[],{"intervention":1633,"totalTrials":13,"cells":1634},"Agomelatine A",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1636,"activeCount":95},[],{"trials":1638,"activeCount":95},[],{"trials":1640,"activeCount":95},[1641],{"nctId":1642,"briefTitle":1643,"status":101,"phases":1644,"primaryCompletion":1645,"completion":1646,"start":1647,"enrollment":1648,"conditions":1649,"interventions":1651},"NCT01108393","Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder",[85],"2012-08","2013-04","2010-05",74,[1650],"Obsessive Compulsive Disorder",[1633],{"trials":1653,"activeCount":95},[],{"trials":1655,"activeCount":95},[],{"trials":1657,"activeCount":95},[],{"intervention":1659,"totalTrials":13,"cells":1660},"Combination therapy (S81694 + paclitaxel) phase I",{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1662,"activeCount":95},[],{"trials":1664,"activeCount":95},[],{"trials":1666,"activeCount":95},[1667],{"nctId":1668,"briefTitle":1669,"status":101,"phases":1670,"primaryCompletion":1671,"completion":1671,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1677},"NCT03411161","S 81694 Plus Paclitaxel in Metastatic Breast Cancer",[84,85],"2020-06-08","2018-01-04",22,[1675,1676],"Metastatic Breast Cancer","Metastatic Triple Negative Breast Cancer",[1659,1678,1679],"Paclitaxel","Combination therapy (S81694 + paclitaxel) phase II",{"trials":1681,"activeCount":95},[],{"trials":1683,"activeCount":95},[],{"trials":1685,"activeCount":95},[],{"intervention":1678,"totalTrials":13,"cells":1687},{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1692,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1689,"activeCount":95},[],{"trials":1691,"activeCount":95},[],{"trials":1693,"activeCount":95},[1694],{"nctId":1668,"briefTitle":1669,"status":101,"phases":1695,"primaryCompletion":1671,"completion":1671,"start":1672,"enrollment":1673,"conditions":1696,"interventions":1697},[84,85],[1675,1676],[1659,1678,1679],{"trials":1699,"activeCount":95},[],{"trials":1701,"activeCount":95},[],{"trials":1703,"activeCount":95},[],{"intervention":1679,"totalTrials":13,"cells":1705},{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1707,"activeCount":95},[],{"trials":1709,"activeCount":95},[],{"trials":1711,"activeCount":95},[1712],{"nctId":1668,"briefTitle":1669,"status":101,"phases":1713,"primaryCompletion":1671,"completion":1671,"start":1672,"enrollment":1673,"conditions":1714,"interventions":1715},[84,85],[1675,1676],[1659,1678,1679],{"trials":1717,"activeCount":95},[],{"trials":1719,"activeCount":95},[],{"trials":1721,"activeCount":95},[],{"intervention":1723,"totalTrials":13,"cells":1724},"S18986",{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1740,"PHASE4":1742,"NA":1744},{"trials":1726,"activeCount":95},[],{"trials":1728,"activeCount":95},[],{"trials":1730,"activeCount":95},[1731],{"nctId":1732,"briefTitle":1733,"status":437,"phases":1734,"primaryCompletion":1735,"completion":1735,"start":1039,"enrollment":1736,"conditions":1737,"interventions":1739},"NCT00202540","Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients",[85],"2006-03-29",38,[1738],"Mild Cognitive Impairment",[1723],{"trials":1741,"activeCount":95},[],{"trials":1743,"activeCount":95},[],{"trials":1745,"activeCount":95},[],{"intervention":1747,"totalTrials":13,"cells":1748},"S 64315 (also referred as MIK665) and azacitidine",{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1750,"activeCount":95},[],{"trials":1752,"activeCount":95},[],{"trials":1754,"activeCount":95},[1755],{"nctId":1756,"briefTitle":1757,"status":101,"phases":1758,"primaryCompletion":1759,"completion":1759,"start":1760,"enrollment":1761,"conditions":1762,"interventions":1764},"NCT04629443","Phase I\u002FII Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia",[84,85],"2023-08-25","2021-02-17",17,[1763],"Acute Myeloid Leukaemia",[1747],{"trials":1766,"activeCount":95},[],{"trials":1768,"activeCount":95},[],{"trials":1770,"activeCount":95},[],{"intervention":1772,"totalTrials":13,"cells":1773},"S 44819 150 mg twice a day",{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1778,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1775,"activeCount":95},[],{"trials":1777,"activeCount":95},[],{"trials":1779,"activeCount":95},[1780],{"nctId":1781,"briefTitle":1782,"status":101,"phases":1783,"primaryCompletion":1784,"completion":1784,"start":1785,"enrollment":1786,"conditions":1787,"interventions":1789},"NCT02877615","Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event",[85],"2019-03-10","2016-12-19",585,[1788],"Post Stroke Recovery",[1772,1790],"S 44819 300 mg twice a day",{"trials":1792,"activeCount":95},[],{"trials":1794,"activeCount":95},[],{"trials":1796,"activeCount":95},[],{"intervention":1790,"totalTrials":13,"cells":1798},{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1800,"activeCount":95},[],{"trials":1802,"activeCount":95},[],{"trials":1804,"activeCount":95},[1805],{"nctId":1781,"briefTitle":1782,"status":101,"phases":1806,"primaryCompletion":1784,"completion":1784,"start":1785,"enrollment":1786,"conditions":1807,"interventions":1808},[85],[1788],[1772,1790],{"trials":1810,"activeCount":95},[],{"trials":1812,"activeCount":95},[],{"trials":1814,"activeCount":95},[],{"intervention":1493,"totalTrials":13,"cells":1816},{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1827,"PHASE4":1829,"NA":1831},{"trials":1818,"activeCount":95},[],{"trials":1820,"activeCount":95},[],{"trials":1822,"activeCount":95},[1823],{"nctId":1485,"briefTitle":1486,"status":101,"phases":1824,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1490,"conditions":1825,"interventions":1826},[85],[19],[1476,1493],{"trials":1828,"activeCount":95},[],{"trials":1830,"activeCount":95},[],{"trials":1832,"activeCount":95},[],{"intervention":1834,"totalTrials":13,"cells":1835},"BAX2398 + 5-FU\u002Fcalcium levofolinate",{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1852,"PHASE4":1854,"NA":1856},{"trials":1837,"activeCount":95},[],{"trials":1839,"activeCount":95},[],{"trials":1841,"activeCount":95},[1842],{"nctId":1843,"briefTitle":1844,"status":101,"phases":1845,"primaryCompletion":1371,"completion":1846,"start":1847,"enrollment":1117,"conditions":1848,"interventions":1850},"NCT02697058","Phase II of BAX2398\u002F5-FU\u002FCalcium Levofolinate in Pancreatic Cancer",[85],"2018-08-28","2016-03-30",[1849],"Metastatic Pancreatic Cancer",[1834,1851],"5-FU\u002Fcalcium levofolinate",{"trials":1853,"activeCount":95},[],{"trials":1855,"activeCount":95},[],{"trials":1857,"activeCount":95},[],{"intervention":1851,"totalTrials":13,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1861,"activeCount":95},[],{"trials":1863,"activeCount":95},[],{"trials":1865,"activeCount":95},[1866],{"nctId":1843,"briefTitle":1844,"status":101,"phases":1867,"primaryCompletion":1371,"completion":1846,"start":1847,"enrollment":1117,"conditions":1868,"interventions":1869},[85],[1849],[1834,1851],{"trials":1871,"activeCount":95},[],{"trials":1873,"activeCount":95},[],{"trials":1875,"activeCount":95},[],{"intervention":1877,"totalTrials":13,"cells":1878},"S95005",{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1880,"activeCount":95},[],{"trials":1882,"activeCount":95},[],{"trials":1884,"activeCount":95},[1885],{"nctId":1886,"briefTitle":1887,"status":101,"phases":1888,"primaryCompletion":1889,"completion":1890,"start":1891,"enrollment":1892,"conditions":1893,"interventions":1894},"NCT03274882","Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies",[85],"2017-12-31","2018-12-03","2017-03-03",26,[16],[1877],{"trials":1896,"activeCount":95},[],{"trials":1898,"activeCount":95},[],{"trials":1900,"activeCount":95},[],{"intervention":1902,"totalTrials":13,"cells":1903},"Combination",{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1920,"PHASE4":1922,"NA":1924},{"trials":1905,"activeCount":95},[],{"trials":1907,"activeCount":95},[],{"trials":1909,"activeCount":95},[1910],{"nctId":1911,"briefTitle":1912,"status":1913,"phases":1914,"primaryCompletion":1915,"completion":1915,"start":1916,"enrollment":95,"conditions":1917,"interventions":1919},"NCT05312372","S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC","WITHDRAWN",[84,85],"2026-06","2025-05",[1918],"Esophageal Squamous Cell Carcinoma",[1902],{"trials":1921,"activeCount":95},[],{"trials":1923,"activeCount":95},[],{"trials":1925,"activeCount":95},[],{"intervention":1927,"totalTrials":13,"cells":1928},"S65487 and azacitidine",{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1944,"PHASE4":1946,"NA":1948},{"trials":1930,"activeCount":95},[],{"trials":1932,"activeCount":95},[],{"trials":1934,"activeCount":95},[1935],{"nctId":1936,"briefTitle":1937,"status":101,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":979,"enrollment":1940,"conditions":1941,"interventions":1943},"NCT04742101","Phase I\u002FII Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia",[84,85],"2026-03-27",57,[1942],"Acute Myeloid Leukemia",[1927],{"trials":1945,"activeCount":95},[],{"trials":1947,"activeCount":95},[],{"trials":1949,"activeCount":95},[],{"intervention":1951,"totalTrials":13,"cells":1952},"SHP674",{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1968,"PHASE4":1970,"NA":1972},{"trials":1954,"activeCount":95},[],{"trials":1956,"activeCount":95},[],{"trials":1958,"activeCount":95},[1959],{"nctId":1960,"briefTitle":1961,"status":101,"phases":1962,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":115,"conditions":1966,"interventions":1967},"NCT04067518","A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia",[85],"2021-02-12","2022-02-04","2019-10-17",[19],[1951],{"trials":1969,"activeCount":95},[],{"trials":1971,"activeCount":95},[],{"trials":1973,"activeCount":95},[],{"intervention":1446,"totalTrials":13,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1986,"PHASE4":1988,"NA":1990},{"trials":1977,"activeCount":95},[],{"trials":1979,"activeCount":95},[],{"trials":1981,"activeCount":95},[1982],{"nctId":1437,"briefTitle":1438,"status":101,"phases":1983,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":1984,"interventions":1985},[85],[1444],[1446,1417,1435],{"trials":1987,"activeCount":95},[],{"trials":1989,"activeCount":95},[],{"trials":1991,"activeCount":95},[],{"intervention":1993,"totalTrials":30,"cells":1994},"UCART19",{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":2021,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":1996,"activeCount":95},[],{"trials":1998,"activeCount":95},[1999,2011],{"nctId":2000,"briefTitle":2001,"status":101,"phases":2002,"primaryCompletion":2003,"completion":2004,"start":2005,"enrollment":2006,"conditions":2007,"interventions":2010},"NCT02808442","Study of UCART19 in Pediatric Patients With Relapsed\u002FRefractory B Acute Lymphoblastic Leukemia",[84],"2020-09-17","2020-11-04","2016-06-03",13,[2008,2009],"Refractory B-cell Acute Lymphoblastic Leukemia","Relapsed B-cell Acute Lymphoblastic Leukemia",[1993],{"nctId":2012,"briefTitle":2013,"status":101,"phases":2014,"primaryCompletion":2015,"completion":2015,"start":2016,"enrollment":2017,"conditions":2018,"interventions":2020},"NCT02746952","Dose Escalation Study of UCART19 in Adult Patients With Relapsed \u002F Refractory B-cell Acute Lymphoblastic Leukaemia",[84],"2020-07-28","2016-08-01",25,[2019],"B-cell Acute Lymphoblastic Leukemia",[1993],{"trials":2022,"activeCount":95},[],{"trials":2024,"activeCount":95},[],{"trials":2026,"activeCount":95},[],{"trials":2028,"activeCount":95},[],{"intervention":237,"totalTrials":30,"cells":2030},{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2049,"PHASE3":2051,"PHASE4":2053,"NA":2055},{"trials":2032,"activeCount":95},[],{"trials":2034,"activeCount":95},[2035,2045],{"nctId":2036,"briefTitle":2037,"status":101,"phases":2038,"primaryCompletion":2039,"completion":2040,"start":2041,"enrollment":2042,"conditions":2043,"interventions":2044},"NCT02481154","Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and\u002For IDH2 Mutation",[84],"2022-10-17","2024-06-19","2015-06",95,[27],[237],{"nctId":228,"briefTitle":229,"status":101,"phases":2046,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":2047,"interventions":2048},[84],[27],[40,237],{"trials":2050,"activeCount":95},[],{"trials":2052,"activeCount":95},[],{"trials":2054,"activeCount":95},[],{"trials":2056,"activeCount":95},[],{"intervention":2058,"totalTrials":13,"cells":2059},"S 95010",{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2073,"PHASE3":2075,"PHASE4":2077,"NA":2079},{"trials":2061,"activeCount":95},[],{"trials":2063,"activeCount":95},[2064],{"nctId":2065,"briefTitle":2066,"status":101,"phases":2067,"primaryCompletion":2068,"completion":2068,"start":2069,"enrollment":234,"conditions":2070,"interventions":2072},"NCT03494712","Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers",[84],"2019-04-10","2018-02-21",[2071],"Cardiovascular Diseases",[2058],{"trials":2074,"activeCount":95},[],{"trials":2076,"activeCount":95},[],{"trials":2078,"activeCount":95},[],{"trials":2080,"activeCount":95},[],{"intervention":2082,"totalTrials":13,"cells":2083},"S65487- initial scheme",{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2107},{"trials":2085,"activeCount":95},[],{"trials":2087,"activeCount":95},[2088],{"nctId":2089,"briefTitle":2090,"status":437,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":125,"conditions":2094,"interventions":2099},"NCT03755154","Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia",[84],"2023-11-06","2019-07-17",[2095,2096,2097,2098],"Relapsed or Refractory Acute Myeloid Leukemia","Relapsed or Refractory Non-Hodgkin Lymphoma","Relapsed or Refractory Multiple Myeloma","Relapsed or Refractory Chronic Lymphocytic Leukemia",[2082,2100],"S65487 - alternative scheme",{"trials":2102,"activeCount":95},[],{"trials":2104,"activeCount":95},[],{"trials":2106,"activeCount":95},[],{"trials":2108,"activeCount":95},[],{"intervention":2100,"totalTrials":13,"cells":2110},{"EARLY_PHASE1":2111,"PHASE1":2113,"PHASE2":2119,"PHASE3":2121,"PHASE4":2123,"NA":2125},{"trials":2112,"activeCount":95},[],{"trials":2114,"activeCount":95},[2115],{"nctId":2089,"briefTitle":2090,"status":437,"phases":2116,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":125,"conditions":2117,"interventions":2118},[84],[2095,2096,2097,2098],[2082,2100],{"trials":2120,"activeCount":95},[],{"trials":2122,"activeCount":95},[],{"trials":2124,"activeCount":95},[],{"trials":2126,"activeCount":95},[],{"intervention":2128,"totalTrials":13,"cells":2129},"S095029",{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2144,"PHASE3":2146,"PHASE4":2148,"NA":2150},{"trials":2131,"activeCount":95},[],{"trials":2133,"activeCount":95},[2134],{"nctId":2135,"briefTitle":2136,"status":101,"phases":2137,"primaryCompletion":2138,"completion":2139,"start":2140,"enrollment":1403,"conditions":2141,"interventions":2142},"NCT05162755","S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers",[84],"2024-02-01","2026-05-05","2021-10-15",[476],[2128,2143],"S95029 and Sym021",{"trials":2145,"activeCount":95},[],{"trials":2147,"activeCount":95},[],{"trials":2149,"activeCount":95},[],{"trials":2151,"activeCount":95},[],{"intervention":2143,"totalTrials":13,"cells":2153},{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2162,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2155,"activeCount":95},[],{"trials":2157,"activeCount":95},[2158],{"nctId":2135,"briefTitle":2136,"status":101,"phases":2159,"primaryCompletion":2138,"completion":2139,"start":2140,"enrollment":1403,"conditions":2160,"interventions":2161},[84],[476],[2128,2143],{"trials":2163,"activeCount":95},[],{"trials":2165,"activeCount":95},[],{"trials":2167,"activeCount":95},[],{"trials":2169,"activeCount":95},[],{"intervention":2171,"totalTrials":13,"cells":2172},"S 55746",{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2174,"activeCount":95},[],{"trials":2176,"activeCount":95},[2177],{"nctId":2178,"briefTitle":2179,"status":101,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2188},"NCT02920697","Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma",[84],"2018-10-22","2014-03",65,[2185,2186,2187],"Chronic Lymphocytic Leukaemia (CLL)","B-Cell Non-Hodgkin Lymphoma (NHL)","Multiple Myeloma (MM)",[2171],{"trials":2190,"activeCount":95},[],{"trials":2192,"activeCount":95},[],{"trials":2194,"activeCount":95},[],{"trials":2196,"activeCount":95},[],{"intervention":2198,"totalTrials":13,"cells":2199},"S 055746",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2214,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2201,"activeCount":95},[],{"trials":2203,"activeCount":95},[2204],{"nctId":2205,"briefTitle":2206,"status":101,"phases":2207,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":288,"conditions":2210,"interventions":2213},"NCT02920541","Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome",[84],"2018-05-24","2015-01",[2211,2212],"Acute Myeloid Leukaemia (AML)","Myelodysplastic Syndrome (MDS)",[2198],{"trials":2215,"activeCount":95},[],{"trials":2217,"activeCount":95},[],{"trials":2219,"activeCount":95},[],{"trials":2221,"activeCount":95},[],{"intervention":344,"totalTrials":13,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2232,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":95},[],{"trials":2227,"activeCount":95},[2228],{"nctId":334,"briefTitle":335,"status":101,"phases":2229,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":2230,"interventions":2231},[84],[16],[49,343,344,345],{"trials":2233,"activeCount":95},[],{"trials":2235,"activeCount":95},[],{"trials":2237,"activeCount":95},[],{"trials":2239,"activeCount":95},[],{"intervention":345,"totalTrials":13,"cells":2241},{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2256},{"trials":2243,"activeCount":95},[],{"trials":2245,"activeCount":95},[2246],{"nctId":334,"briefTitle":335,"status":101,"phases":2247,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":2248,"interventions":2249},[84],[16],[49,343,344,345],{"trials":2251,"activeCount":95},[],{"trials":2253,"activeCount":95},[],{"trials":2255,"activeCount":95},[],{"trials":2257,"activeCount":95},[],{"intervention":2259,"totalTrials":13,"cells":2260},"S64315 once a week",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2274,"PHASE3":2276,"PHASE4":2278,"NA":2280},{"trials":2262,"activeCount":95},[],{"trials":2264,"activeCount":95},[2265],{"nctId":2266,"briefTitle":2267,"status":101,"phases":2268,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":1736,"conditions":2271,"interventions":2272},"NCT02979366","Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome",[84],"2020-05-11","2017-03-15",[2211,2212],[2259,2273],"S64315 twice a week",{"trials":2275,"activeCount":95},[],{"trials":2277,"activeCount":95},[],{"trials":2279,"activeCount":95},[],{"trials":2281,"activeCount":95},[],{"intervention":2273,"totalTrials":13,"cells":2283},{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2292,"PHASE3":2294,"PHASE4":2296,"NA":2298},{"trials":2285,"activeCount":95},[],{"trials":2287,"activeCount":95},[2288],{"nctId":2266,"briefTitle":2267,"status":101,"phases":2289,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":1736,"conditions":2290,"interventions":2291},[84],[2211,2212],[2259,2273],{"trials":2293,"activeCount":95},[],{"trials":2295,"activeCount":95},[],{"trials":2297,"activeCount":95},[],{"trials":2299,"activeCount":95},[],{"intervention":446,"totalTrials":13,"cells":2301},{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2310,"PHASE3":2312,"PHASE4":2314,"NA":2316},{"trials":2303,"activeCount":95},[],{"trials":2305,"activeCount":95},[2306],{"nctId":435,"briefTitle":436,"status":437,"phases":2307,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":2308,"interventions":2309},[84],[443,444],[446,446,446,447,448,449],{"trials":2311,"activeCount":95},[],{"trials":2313,"activeCount":95},[],{"trials":2315,"activeCount":95},[],{"trials":2317,"activeCount":95},[],{"intervention":447,"totalTrials":13,"cells":2319},{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2328,"PHASE3":2330,"PHASE4":2332,"NA":2334},{"trials":2321,"activeCount":95},[],{"trials":2323,"activeCount":95},[2324],{"nctId":435,"briefTitle":436,"status":437,"phases":2325,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":2326,"interventions":2327},[84],[443,444],[446,446,446,447,448,449],{"trials":2329,"activeCount":95},[],{"trials":2331,"activeCount":95},[],{"trials":2333,"activeCount":95},[],{"trials":2335,"activeCount":95},[],{"intervention":119,"totalTrials":13,"cells":2337},{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2346,"PHASE3":2348,"PHASE4":2350,"NA":2352},{"trials":2339,"activeCount":95},[],{"trials":2341,"activeCount":95},[2342],{"nctId":110,"briefTitle":111,"status":101,"phases":2343,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":2344,"interventions":2345},[84],[117],[54,119],{"trials":2347,"activeCount":95},[],{"trials":2349,"activeCount":95},[],{"trials":2351,"activeCount":95},[],{"trials":2353,"activeCount":95},[],{"intervention":2355,"totalTrials":13,"cells":2356},"89Zr-S095012 tracer and S095012 will be administered via an IV",{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2370,"PHASE3":2372,"PHASE4":2374,"NA":2376},{"trials":2358,"activeCount":95},[],{"trials":2360,"activeCount":95},[2361],{"nctId":2362,"briefTitle":2363,"status":437,"phases":2364,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":25,"conditions":2367,"interventions":2369},"NCT05638334","Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours",[84],"2024-06-14","2022-11-21",[2368],"Advanced Solid Tumor",[2355],{"trials":2371,"activeCount":95},[],{"trials":2373,"activeCount":95},[],{"trials":2375,"activeCount":95},[],{"trials":2377,"activeCount":95},[],{"intervention":140,"totalTrials":13,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2388,"PHASE3":2390,"PHASE4":2392,"NA":2394},{"trials":2381,"activeCount":95},[],{"trials":2383,"activeCount":95},[2384],{"nctId":132,"briefTitle":133,"status":101,"phases":2385,"primaryCompletion":135,"completion":135,"start":136,"enrollment":115,"conditions":2386,"interventions":2387},[84],[138],[54,140,141,142,143,144,145],{"trials":2389,"activeCount":95},[],{"trials":2391,"activeCount":95},[],{"trials":2393,"activeCount":95},[],{"trials":2395,"activeCount":95},[],{"intervention":141,"totalTrials":13,"cells":2397},{"EARLY_PHASE1":2398,"PHASE1":2400,"PHASE2":2406,"PHASE3":2408,"PHASE4":2410,"NA":2412},{"trials":2399,"activeCount":95},[],{"trials":2401,"activeCount":95},[2402],{"nctId":132,"briefTitle":133,"status":101,"phases":2403,"primaryCompletion":135,"completion":135,"start":136,"enrollment":115,"conditions":2404,"interventions":2405},[84],[138],[54,140,141,142,143,144,145],{"trials":2407,"activeCount":95},[],{"trials":2409,"activeCount":95},[],{"trials":2411,"activeCount":95},[],{"trials":2413,"activeCount":95},[],{"intervention":142,"totalTrials":13,"cells":2415},{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2424,"PHASE3":2426,"PHASE4":2428,"NA":2430},{"trials":2417,"activeCount":95},[],{"trials":2419,"activeCount":95},[2420],{"nctId":132,"briefTitle":133,"status":101,"phases":2421,"primaryCompletion":135,"completion":135,"start":136,"enrollment":115,"conditions":2422,"interventions":2423},[84],[138],[54,140,141,142,143,144,145],{"trials":2425,"activeCount":95},[],{"trials":2427,"activeCount":95},[],{"trials":2429,"activeCount":95},[],{"trials":2431,"activeCount":95},[],{"intervention":143,"totalTrials":13,"cells":2433},{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2442,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2435,"activeCount":95},[],{"trials":2437,"activeCount":95},[2438],{"nctId":132,"briefTitle":133,"status":101,"phases":2439,"primaryCompletion":135,"completion":135,"start":136,"enrollment":115,"conditions":2440,"interventions":2441},[84],[138],[54,140,141,142,143,144,145],{"trials":2443,"activeCount":95},[],{"trials":2445,"activeCount":95},[],{"trials":2447,"activeCount":95},[],{"trials":2449,"activeCount":95},[],{"intervention":144,"totalTrials":13,"cells":2451},{"EARLY_PHASE1":2452,"PHASE1":2454,"PHASE2":2460,"PHASE3":2462,"PHASE4":2464,"NA":2466},{"trials":2453,"activeCount":95},[],{"trials":2455,"activeCount":95},[2456],{"nctId":132,"briefTitle":133,"status":101,"phases":2457,"primaryCompletion":135,"completion":135,"start":136,"enrollment":115,"conditions":2458,"interventions":2459},[84],[138],[54,140,141,142,143,144,145],{"trials":2461,"activeCount":95},[],{"trials":2463,"activeCount":95},[],{"trials":2465,"activeCount":95},[],{"trials":2467,"activeCount":95},[],{"intervention":145,"totalTrials":13,"cells":2469},{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2478,"PHASE3":2480,"PHASE4":2482,"NA":2484},{"trials":2471,"activeCount":95},[],{"trials":2473,"activeCount":95},[2474],{"nctId":132,"briefTitle":133,"status":101,"phases":2475,"primaryCompletion":135,"completion":135,"start":136,"enrollment":115,"conditions":2476,"interventions":2477},[84],[138],[54,140,141,142,143,144,145],{"trials":2479,"activeCount":95},[],{"trials":2481,"activeCount":95},[],{"trials":2483,"activeCount":95},[],{"trials":2485,"activeCount":95},[],{"intervention":2487,"totalTrials":13,"cells":2488},"S 64315 (also referred as MIK665) and venetoclax",{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2503,"PHASE3":2505,"PHASE4":2507,"NA":2509},{"trials":2490,"activeCount":95},[],{"trials":2492,"activeCount":95},[2493],{"nctId":2494,"briefTitle":2495,"status":101,"phases":2496,"primaryCompletion":2497,"completion":2498,"start":2499,"enrollment":2500,"conditions":2501,"interventions":2502},"NCT03672695","Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.",[84],"2022-11-12","2023-05-30","2018-11-28",37,[1763],[2487],{"trials":2504,"activeCount":95},[],{"trials":2506,"activeCount":95},[],{"trials":2508,"activeCount":95},[],{"trials":2510,"activeCount":95},[],{"intervention":2512,"totalTrials":13,"cells":2513},"Other",{"EARLY_PHASE1":2514,"PHASE1":2516,"PHASE2":2528,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2515,"activeCount":95},[],{"trials":2517,"activeCount":95},[2518],{"nctId":2519,"briefTitle":2520,"status":101,"phases":2521,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":2525,"interventions":2527},"NCT04744636","Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus",[84],"2018-09-15","2017-04-03",100,[2526],"Type 2 Diabetes Mellitus",[2512,2512],{"trials":2529,"activeCount":95},[],{"trials":2531,"activeCount":95},[],{"trials":2533,"activeCount":95},[],{"trials":2535,"activeCount":95},[],{"intervention":2537,"totalTrials":13,"cells":2538},"ONIVYDE",{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2547,"NA":2549},{"trials":2540,"activeCount":95},[],{"trials":2542,"activeCount":95},[],{"trials":2544,"activeCount":95},[],{"trials":2546,"activeCount":95},[],{"trials":2548,"activeCount":95},[],{"trials":2550,"activeCount":95},[2551],{"nctId":2552,"briefTitle":2553,"status":101,"phases":2554,"primaryCompletion":2555,"completion":2555,"start":2556,"enrollment":2557,"conditions":2558,"interventions":2559},"NCT03446872","Post Marketing Surveillance Study for ONIVYDE® in South Korea",[],"2020-08-29","2018-03-08",94,[1849],[2537,2560,2561],"5-fluorouracil","Leucovorin",{"intervention":2560,"totalTrials":13,"cells":2563},{"EARLY_PHASE1":2564,"PHASE1":2566,"PHASE2":2568,"PHASE3":2570,"PHASE4":2572,"NA":2574},{"trials":2565,"activeCount":95},[],{"trials":2567,"activeCount":95},[],{"trials":2569,"activeCount":95},[],{"trials":2571,"activeCount":95},[],{"trials":2573,"activeCount":95},[],{"trials":2575,"activeCount":95},[2576],{"nctId":2552,"briefTitle":2553,"status":101,"phases":2577,"primaryCompletion":2555,"completion":2555,"start":2556,"enrollment":2557,"conditions":2578,"interventions":2579},[],[1849],[2537,2560,2561],{"intervention":2561,"totalTrials":13,"cells":2581},{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2586,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2583,"activeCount":95},[],{"trials":2585,"activeCount":95},[],{"trials":2587,"activeCount":95},[],{"trials":2589,"activeCount":95},[],{"trials":2591,"activeCount":95},[],{"trials":2593,"activeCount":95},[2594],{"nctId":2552,"briefTitle":2553,"status":101,"phases":2595,"primaryCompletion":2555,"completion":2555,"start":2556,"enrollment":2557,"conditions":2596,"interventions":2597},[],[1849],[2537,2560,2561]]